{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:36Z","timestamp":1791181236056,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/md.0000000000000673","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T14:19:49Z","timestamp":1431008389000},"page":"e673","source":"Crossref","is-referenced-by-count":17,"title":["Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure"],"prefix":"10.1097","volume":"94","author":[{"given":"Bella","family":"Ungar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Haj-Natour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Yavzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Loebstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaakov","family":"Maor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Avidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Eliakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210309","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R2-2-20210309","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohns disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-2-20210309","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-2-20210309","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.","volume":"63","author":"Ungar","year":"2013","journal-title":"Gut"},{"key":"R5-2-20210309","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient.","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R6-2-20210309","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R7-2-20210309","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohns disease.","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R8-2-20210309","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease.","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-2-20210309","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease.","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"R10-2-20210309","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2036.2006.03066.x","article-title":"Review article: biological drugs in Crohns disease.","volume":"24","author":"Kamm","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-2-20210309","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ibd.21831","article-title":"Therapeutic drug monitoring of biologics for inflammatory bowel disease.","volume":"18","author":"Colombel","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R12-2-20210309","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohns disease.","volume":"17","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-2-20210309","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohns disease.","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"R14-2-20210309","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohns disease.","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R15-2-20210309","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R16-2-20210309","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.12507","article-title":"Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.","volume":"38","author":"Moss","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-2-20210309","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/gut.2004.056358","article-title":"Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.","volume":"54","author":"Higgins","year":"2005","journal-title":"Gut"},{"key":"R18-2-20210309","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohns-disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"R19-2-20210309","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohns disease activity and Harvey-Bradshaw indices in assessing Crohns disease severity.","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-2-20210309","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohns disease.","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-2-20210309","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful.","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"R22-2-20210309","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R23-2-20210309","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-2-20210309","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-2-20210309","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.20469","article-title":"The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.","volume":"50","author":"Criswell","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R26-2-20210309","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ibd.21174","article-title":"Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.","volume":"16","author":"Dubinsky","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"R27-2-20210309","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1572-0241.2007.01277.x","article-title":"Risk factors for perianal Crohns disease: the role of genotype, phenotype, and ethnicity.","volume":"102","author":"Karban","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R28-2-20210309","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1572-0241.2004.04156.x","article-title":"NOD2CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohns disease.","volume":"99","author":"Karban","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R29-2-20210309","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10620-008-0326-7","article-title":"Disease behavior in children with Crohns disease: the effect of disease duration, ethnicity, genotype, and phenotype.","volume":"54","author":"Shaoul","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R30-2-20210309","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/MIB.0b013e31828828d3","article-title":"Thiopurine effectiveness in patients with Crohns disease: a study of genetic and clinical predictive factors.","volume":"19","author":"Koifman","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R31-2-20210309","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohns disease: a post-hoc analysis from ACCENT I.","volume":"35","author":"Reinisch","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-2-20210309","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"R33-2-20210309","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"R34-2-20210309","first-page":"9","article-title":"Infliximab therapy for moderately severe Crohns disease and ulcerative colitis: a retrospective comparison over 6 years.","volume":"4","author":"Alzafiri","year":"2011","journal-title":"Clin Exp Gastroenterol"},{"key":"R35-2-20210309","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"R36-2-20210309","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohns disease.","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:28Z","timestamp":1620960148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201505020-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":36,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000673","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}